Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Mesenchymal Stem Cells for Critical Limb Ischemia
NCT03239535Phase 2Unknown
- Sponsor
- Federal Research Clinical Center of the FMBA
- Start
- Oct 2013
- Primary completion
- Aug 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in critical limb ischemia (CLI), sponsored by Federal Research Clinical Center of the FMBA. Primary endpoint: Adverse events at 24 months. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03239535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239535.